Met Kinase Inhibitor is a pyrrole indolinone compound acting as an ATP-competitive inhibitor of Met kinase activity. Met Kinase Inhibitor shows great (>60-fold) selectivity over Flk and Ron, FGFR-1, c-Src, Cdk2, PDGFRβ, EGFR, and Tie-2 (>400-fold). Met Kinase Inhibitor demonstrated inhibitory effects on HGF/SF-stimulated cellular signaling and Med-mediated tumorigenisis.
Ma. P. C., et al. 2005. Cancer Res. 65, 1479. Berthou, S., et al. 2004. Oncogene 23, 5387. Wang, X., et al. 2003. Mol. Cancer Ther. 2, 1085. Sattler, M., et al. 2003. Cancer Res. 63, 5462.
See how others have used Met Kinase Inhibitor. Click on the entry to view the PubMed entry .
PMID: # 26940070 Yong, X. et al. 2016. Cancer letters. 374: 292-303.
PMID: # 24835851 Lim, YC. et al. 2014. Oral Oncol. 50: 633-9.
PMID: # 22205724 Kindrachuk, J. et al. 2012. Mol. Cell Proteomics. 11: M111.015701.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.